Literature DB >> 24335004

Treating percutaneous coronary intervention-related myocardial injury with metformin.

John W Calvert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24335004      PMCID： PMC3928971          DOI： 10.1159/000356875

Source DB:  PubMed          Journal:  Cardiology        ISSN： 0008-6312            Impact factor:   1.869


× No keyword cloud information.
  17 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

Review 2.  Peri-procedural myocardial injury: 2005 update.

Authors:  Joerg Herrmann
Journal:  Eur Heart J       Date:  2005-09-21       Impact factor: 29.983

3.  Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy).

Authors:  James C Blankenship; Tom Haldis; Frederick Feit; Tingfei Hu; Neal S Kleiman; Eric J Topol; A Michael Lincoff
Journal:  Am J Cardiol       Date:  2006-04-07       Impact factor: 2.778

4.  A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?

Authors:  Roger K G Moore; Robert Lowe; Anthony D Grayson; John L Morris; Raphael A Perry; Rodney H Stables
Journal:  Int J Cardiol       Date:  2006-07-25       Impact factor: 4.164

Review 5.  Myonecrosis after revascularization procedures.

Authors:  R M Califf; A E Abdelmeguid; R E Kuntz; J J Popma; C J Davidson; E A Cohen; N S Kleiman; K W Mahaffey; E J Topol; C J Pepine; R J Lipicky; C B Granger; R A Harrington; B E Tardiff; B S Crenshaw; R P Bauman; B D Zuckerman; B R Chaitman; J A Bittl; E M Ohman
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

6.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

Authors:  L Schwartz; M G Bourassa; J Lespérance; H E Aldridge; F Kazim; V A Salvatori; M Henderson; R Bonan; P R David
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

7.  Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase.

Authors:  Bradley J Davis; Zhonglin Xie; Benoit Viollet; Ming-Hui Zou
Journal:  Diabetes       Date:  2006-02       Impact factor: 9.461

Review 8.  Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion.

Authors:  D J Lefer
Journal:  New Horiz       Date:  1995-02

9.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.

Authors:  Raymond R Russell; Ji Li; David L Coven; Marc Pypaert; Christoph Zechner; Monica Palmeri; Frank J Giordano; James Mu; Morris J Birnbaum; Lawrence H Young
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.

Authors:  John W Calvert; Susheel Gundewar; Saurabh Jha; James J M Greer; William H Bestermann; Rong Tian; David J Lefer
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.